341
Participants
Start Date
June 28, 2019
Primary Completion Date
December 31, 2026
Study Completion Date
March 31, 2027
IDE196
IDE196 dosed orally, twice daily for each 28-day cycle
Binimetinib
Binimetinib dosed orally, twice daily for each 28-day cycle
Crizotinib
Crizotinib dosed orally, twice daily for each 28-day cycle
RECRUITING
Columbia University Medical Center - Herbert Irving Pavilion, New York
RECRUITING
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
RECRUITING
Duke University Medical Center, Durham
RECRUITING
The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
RECRUITING
University of Cincinnati Cancer Center, Cincinnati
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
UCLA Medical Center, Los Angeles
RECRUITING
San Francisco Oncology Associates, San Francisco
RECRUITING
Westmead Hospital, Sydney
RECRUITING
Princess Margaret Cancer Centre, Toronto
Lead Sponsor
IDEAYA Biosciences
INDUSTRY